Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

CRISPR Therapeutics (CRSP) proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be held this year. Morrison currently serves as CEO and ...

The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team ...